Science Explorer Back to mapMap
Discussion
Researcher · Genomics Institute of the Novartis Research Foundation · United States

Kathryn B. Grandinetti

Kathryn B. Grandinetti publishes mostly in Molecular Biology, Oncology and Neurology, on topics such as Melanoma and MAPK Pathways, Neuroblastoma Research and Treatments and Epigenetics and DNA Methylation.

ORCID 0009-0000-6917-0372 OpenAlex
World rank
#1,419,272
of 7,710,434 ranked researchers
Rank in United States
#447,658
of 1,627,098
Works
56
Citations
741
Citations per work
13.2
h-index
12
i10-index 12Top 65% in Molecular Biology
Kathryn B. Grandinetti

What does Kathryn B. Grandinetti research?

Kathryn B. Grandinetti's work is mostly in Biochemistry, Genetics and Molecular Biology (50%), Medicine (24%), Immunology and Microbiology (4%).

Life Sciences: 30 works · 53.7% of their workBiochemistry, Genetics and Molecular Biology: 28 works · 50.0% of their workMolecular Biology: 24 works · 42.6% of their workCancer Research: 2 works · 3.7% of their workCell Biology: 2 works · 3.7% of their workImmunology and Microbiology: 2 works · 3.7% of their workImmunology: 2 works · 3.7% of their workHealth Sciences: 13 works · 24.1% of their workMedicine: 13 works · 24.1% of their workOncology: 8 works · 14.8% of their workNeurology: 5 works · 9.3% of their workEverything else: 12 works · 22.2% of their workTHEIR WORKKathryn B.Grandinetti56works
Life Sciences54%Health Sciences24%

Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.

The fields and subfields, with their numbers
    1. Biochemistry, Genetics and Molecular Biology2850.0%
    2. Immunology and Microbiology23.7%
    1. Medicine1324.1%
  3. Everything else1222.2%
  1. 1Molecular Biology43% of their works
  2. 2Oncology15% of their works
  3. 3Neurology9% of their works
  4. 4Cell Biology4% of their works
  5. 5Immunology4% of their works
  6. 6Cancer Research4% of their works

Research topics

Which keywords describe Kathryn B. Grandinetti's research?

The keywords of their largest research topics: Therapy, ALK, BRAF gene, Chemotherapy, MAP Kinase, Neuroblastoma, Cancer and Cetuximab.

Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.

All 19 words, with their numbers
  1. Therapy82 topics
  2. ALK51 topic
  3. BRAF gene51 topic
  4. Chemotherapy52 topics
  5. MAP Kinase51 topic
  6. Neuroblastoma51 topic
  7. Cancer42 topics
  8. Cetuximab31 topic
  9. DNA Methylation31 topic
  10. FGF2131 topic
  11. Fibroblast Growth Factor31 topic
  12. Histone Modification31 topic
  13. KRAS Mutations31 topic
  14. Breast Cancer21 topic
  15. Chromatin21 topic
  16. HER221 topic
  17. Transcription21 topic
  18. Gene Expression11 topic
  19. MicroRNA11 topic

Where does Kathryn B. Grandinetti work?

Kathryn B. Grandinetti's main affiliation in the publication record is Genomics Institute of the Novartis Research Foundation, United States.

How many publications and citations does Kathryn B. Grandinetti have?

OpenAlex counts 56 works and 741 citations for Kathryn B. Grandinetti, an h-index of 12, ranking #1,419,272 of 7,710,434 researchers worldwide on the quality score.

Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.

Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.

Discussion

Ask a question or share a note about Kathryn B. Grandinetti. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.